Table III.
Association between the expression of CXCR1/2 and indicators of proliferation, growth, apoptosis, angiogenesis, invasion and metastasis.
| CXCR1/2 expression
|
||||
|---|---|---|---|---|
| Indicator expression | Negative (n=1) | Weak (n=45) | Strong (n=23) | P-value |
| Phosphorylation | ||||
| AKT | 0.339 | |||
| Negative | 0 | 5 | 0 | |
| Weak | 1 | 25 | 13 | |
| Strong | 0 | 15 | 10 | |
| pAKT | 0.032 | |||
| Negative | 1 | 1 | 1 | |
| Weak | 0 | 15 | 6 | |
| Strong | 0 | 29 | 16 | |
| ERK | 0.725 | |||
| Negative | 0 | 0 | 0 | |
| Weak | 1 | 9 | 6 | |
| Strong | 0 | 36 | 17 | |
| pERK | <0.001 | |||
| Negative | 0 | 2 | 0 | |
| Weak | 1 | 19 | 1 | |
| Strong | 0 | 24 | 22 | |
| Proliferation and growth | ||||
| Ki-67 | 0.456 | |||
| Negative | 1 | 6 | 5 | |
| Weak | 0 | 28 | 11 | |
| Strong | 0 | 11 | 7 | |
| Cyclin D1 | 0.049 | |||
| Negative | 0 | 8 | 2 | |
| Weak | 1 | 32 | 13 | |
| Strong | 0 | 5 | 8 | |
| EGFR | 0.013 | |||
| Negative | 1 | 14 | 3 | |
| Weak | 0 | 25 | 12 | |
| Strong | 0 | 6 | 8 | |
| Apoptosis | ||||
| Bcl-2 | 0.003 | |||
| Negative | 0 | 4 | 0 | |
| Weak | 1 | 21 | 10 | |
| Strong | 0 | 20 | 13 | |
| Bax | 0.103 | |||
| Negative | 1 | 6 | 3 | |
| Weak | 0 | 34 | 15 | |
| Strong | 0 | 5 | 5 | |
| Angiogenesis | ||||
| VEGF | 0.678 | |||
| Negative | 0 | 2 | 1 | |
| Weak | 1 | 23 | 12 | |
| Strong | 0 | 20 | 10 | |
| MVD | 0.001 | |||
| <20 | 1 | 31 | 9 | |
| ≥20 | 0 | 14 | 14 | |
| Invasion and metastasis | ||||
| MMP-9 | 0.013 | |||
| Negative | 1 | 11 | 1 | |
| Weak | 0 | 29 | 16 | |
| Strong | 0 | 5 | 6 | |
| MMP-2 | 0.027 | |||
| Negative | 1 | 14 | 6 | |
| Weak | 0 | 30 | 15 | |
| Strong | 0 | 1 | 2 | |
| TIMP-2 | 0.843 | |||
| Negative | 0 | 24 | 11 | |
| Weak | 1 | 21 | 11 | |
| Strong | 0 | 0 | 1 | |
| E-cadherin | 0.414 | |||
| Negative | 0 | 12 | 4 | |
| Weak | 1 | 28 | 17 | |
| Strong | 0 | 5 | 2 | |
Tumor samples of patients were divided into negative, weak and positive groups of immunohistochemical expression. The tumor samples were divided into high and low MVD groups assessed with the mean microvessel density value of 20 as the cut-off value. CXCR1/2, C-X-C chemokine receptor types 1/2; MVD, microvessel density.